5 Key Takeaways

• 1

  Bayer plans to invest $2.2 billion in a New Albany, Ohio, pharmaceutical campus, with drug substance operations expected in 2031 and drug product operations in 2034.

• 2

  Genentech broke ground on a $750 million Hillsboro, Oregon, expansion that will add device fill-finish capabilities and is expected to begin commercial operations in 2031.

• 3

  Sanofi opened a C$925 million Toronto facility for end-to-end Fluzone High-Dose manufacturing, with production expected to begin in early 2027 pending regulatory approval.

• 4

  Merck KGaA is investing approximately €13 million to add biological buffer manufacturing at its Bengaluru site, alongside existing chemistry capabilities.

• 5

  VERDOT opened a Saint-Beauzire, France, facility that increases manufacturing capacity by 150% for chromatography, filtration, and custom downstream purification equipment.